An immunofluorescent assay with anti-SUZ12 antibody revealed that fewer than 50% Ad-AS-TK transduced BP-CML cells were SUZ12-positive, and more than 70% control cells were SUZ12-positive (Figure 4). This evidence concerns the gene TKT and chronic myelogenous leukemia, BCR-ABL1 positive.